CARMAT |
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.63 EUR | -3.97% |
|
-4.34% | -45.75% |
| Mar. 25 | Carmat: final agreement with creditors | CF |
| Mar. 25 | Carmat Secures Two-year Extensions for Bank Loans | MT |
| Sales 2023 | 2.8M 2.99M | Sales 2024 * | 25.94M 27.71M | Capitalization | 93.67M 100M |
|---|---|---|---|---|---|
| Net income 2023 | -53M -56.63M | Net income 2024 * | -39M -41.67M | EV / Sales 2023 | 59.2 x |
| Net Debt 2023 * | 49.63M 53.03M | Net Debt 2024 * | 78.97M 84.37M | EV / Sales 2024 * | 6.66 x |
| P/E ratio 2023 * |
-1.83
x | P/E ratio 2024 * |
-2.99
x | Employees | 177 |
| Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 85.45% |
More Fundamentals
* Assessed data
More news
Latest transcript on CARMAT
More press releases
More news
| 1 day | -2.12% | ||
| 1 week | -2.63% | ||
| Current month | -10.09% | ||
| 1 month | -6.33% | ||
| 3 months | -16.76% | ||
| 6 months | +16.35% | ||
| Current year | -44.78% |
1 week
3.70
3.92
1 month
3.704.40
Current year
3.667.72
1 year
3.009.99
3 years
3.0031.70
5 years
3.0036.00
10 years
3.0096.00
| Managers | Title | Age | Since |
|---|---|---|---|
Stéphane Piat
CEO | Chief Executive Officer | - | 16-08-31 |
Alain Carpentier
FOU | Founder | 91 | 08-06-24 |
| Director of Finance/CFO | - | 18-12-11 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Alexandre Conroy
CHM | Chairman | 61 | 22-12-21 |
| Director/Board Member | 85 | 16-04-11 | |
Pierre Bastid
BRD | Director/Board Member | 69 | 18-04-04 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-24 | 3.63 | -3.97% | 57 256 |
| 24-04-23 | 3.78 | 0.00% | 25,402 |
| 24-04-22 | 3.78 | -0.66% | 20,171 |
| 24-04-19 | 3.805 | +0.13% | 16,870 |
| 24-04-18 | 3.8 | 0.00% | 16,491 |
Real-time Euronext Paris, April 24, 2024 at 09:16 am EDT
More quotes
CARMAT specializes in the development of a fully implantable orthotopic artificial heart, its electrical power supply system, and its telediagnostics system. The artificial heart is intended for patients with advanced cardiac insufficiency who are ineligible for a transplant and have exhausted all medication alternatives.
Calendar
2024-04-23
- Q4 2023 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
3.78
EUR
Average target price
14.22
EUR
Spread / Average Target
+276.19%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -44.78% | 100M | |
| +11.84% | 127B | |
| -8.67% | 10.68B | |
| -1.71% | 8.59B | |
| +14.99% | 7.09B | |
| +27.16% | 5.07B | |
| +6.81% | 3.39B | |
| -0.98% | 3.04B | |
| -13.77% | 2.02B | |
| -9.83% | 2B |
- Stock Market
- Equities
- ALCAR Stock
